Pharming Group N.V. (PHAR) Stock Analysis
Oversold Bounce setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $12.55, but acceptable to hold if already in. Reason: Market cap $0.91B below $1B minimum.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1... Read more
Hold if already holding. Not a fresh buy at $12.55, but acceptable to hold if already in. Reason: Market cap $0.91B below $1B minimum. Chart setup: Oversold RSI 27, near Bollinger lower, volume surge. Market cap $0.91B below $1B minimum. Not in investable universe. Score 5.5/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Pharming Group N.V.
Latest news
- Pharming Group Sets May 28, 2026 AGM With Key Governance and Capital Measures on Agenda - TipRanks — TipRanks neutral
- Pharming Group N.V. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:PHAR) 2026-05-07 - Seeking Alpha — Seeking Alpha neutral
- Pharming Posts Mixed Q1 2026 as Joenja® Growth Offsets RUCONEST® Decline and Global Label Expansion Advances - TipRanks — TipRanks positive
- PHAR - Pharming Group N.V. ADS each representing 10 stock news, filings & ratings - Quantisnow — Quantisnow neutral
- Pharming Group announces presentations at CIS 2026 Annual - GlobeNewswire — GlobeNewswire neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $12.55, but acceptable to hold if already in. Reason: Market cap $0.91B below $1B minimum. Chart setup: Oversold RSI 27, near Bollinger lower, volume surge. Market cap $0.91B below $1B minimum. Not in investable universe. Target $29.20 (+132.7%), stop $11.74 (−6.9%), A.R:R 9.6:1. Score 5.5/10, moderate confidence.
Take-profit target: $29.20 (+131.4% upside). Target $29.20 (+132.7%), stop $11.74 (−6.9%), A.R:R 9.6:1. Stop-loss: $11.74.
Market cap $0.91B below $1B minimum.
Pharming Group N.V. trades at a P/E of 68.0 (forward 44.5). TrendMatrix value score: 5.9/10. Verdict: Hold.
14 analysts cover PHAR with a consensus score of 4.4/5. Average price target: $34.
What does Pharming Group N.V. do?Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and...
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.